NASDAQ:OSUR - OraSure Technologies Stock Price, News, & Analysis

OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."

OraSure Technologies, Inc. (NASDAQ:OSUR) released its quarterly earnings results on Wednesday, August, 8th. The medical instruments supplier reported $0.07 earnings per share for the quarter, beating analysts' consensus estimates of $0.04 by $0.03. The medical instruments supplier earned $43.60 million during the quarter, compared to the consensus estimate of $42.24 million. OraSure Technologies had a net margin of 8.38% and a return on equity of 5.85%. The firm's quarterly revenue was up 8.5% on a year-over-year basis. During the same period in the previous year, the business earned $0.09 earnings per share. View OraSure Technologies' Earnings History.

OraSure Technologies is scheduled to release their next quarterly earnings announcement on Wednesday, November, 7th 2018. View Earnings Estimates for OraSure Technologies.

OraSure Technologies issued an update on its third quarter earnings guidance on Wednesday, August, 8th. The company provided earnings per share (EPS) guidance of $0.10-0.12 for the period, compared to the Thomson Reuters consensus EPS estimate of $0.11. The company issued revenue guidance of $44-45.5 million, compared to the consensus revenue estimate of $43.72 million.

3 brokerages have issued twelve-month price targets for OraSure Technologies' shares. Their forecasts range from $23.00 to $24.00. On average, they anticipate OraSure Technologies' stock price to reach $23.50 in the next twelve months. This suggests a possible upside of 53.3% from the stock's current price. View Analyst Price Targets for OraSure Technologies.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for OraSure Technologies.

Some companies that are related to OraSure Technologies include NuVasive (NUVA), Merit Medical Systems (MMSI), Irhythm Technologies (IRTC), Tandem Diabetes Care (TNDM), Glaukos (GKOS), Nevro (NVRO), Luminex (LMNX), Mazor Robotics (MZOR), Cardiovascular Systems (CSII), AtriCure (ATRC), Cryolife (CRY), Tactile Systems Technology (TCMD), K2M Group (KTWO), Atrion (ATRI) and Orthofix Medical (OFIX).

Headlines about OSUR stock have trended somewhat positive recently, Accern reports. The research group identifies positive and negative press coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. OraSure Technologies earned a news and rumor sentiment score of 0.18 on Accern's scale. They also assigned media stories about the medical instruments supplier an impact score of 46.57 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the stock's share price in the next several days. View Recent Headlines for OraSure Technologies.

OraSure Technologies' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (13.89%), Renaissance Technologies LLC (6.38%), Dimensional Fund Advisors LP (4.63%), Fred Alger Management Inc. (4.41%), Peregrine Capital Management LLC (1.72%) and Emerald Advisers Inc. PA (1.65%). Company insiders that own OraSure Technologies stock include Anthony Zezzo II, Brian Smith, Charles W Patrick, Douglas A Michels, Jack E Jerrett, Mara G Aspinall, Mark L Kuna, Michael Celano, Ronald H Spair, Ronny B Lancaster and Stephen S Phd Tang. View Institutional Ownership Trends for OraSure Technologies.

OSUR stock was sold by a variety of institutional investors in the last quarter, including Robeco Institutional Asset Management B.V., Fisher Asset Management LLC, Renaissance Technologies LLC, Thompson Siegel & Walmsley LLC, Royce & Associates LP, Citadel Advisors LLC, Voya Investment Management LLC and Wells Fargo & Company MN. Company insiders that have sold OraSure Technologies company stock in the last year include Brian Smith, Charles W Patrick, Douglas A Michels and Stephen S Phd Tang. View Insider Buying and Selling for OraSure Technologies.

OSUR stock was purchased by a variety of institutional investors in the last quarter, including Fred Alger Management Inc., BlackRock Inc., Casdin Capital LLC, Emerald Advisers Inc. PA, Emerald Mutual Fund Advisers Trust, American Capital Management Inc., Penn Capital Management Co. Inc. and Bank of America Corp DE. View Insider Buying and Selling for OraSure Technologies.

Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of OSUR stock can currently be purchased for approximately $15.33.

OraSure Technologies has a market capitalization of $949.41 million and generates $167.06 million in revenue each year. The medical instruments supplier earns $30.94 million in net income (profit) each year or $0.51 on an earnings per share basis. OraSure Technologies employs 377 workers across the globe.

OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier can be reached via phone at 610-882-1820 or via email at [email protected]